Correction to “Comprehensive Characterization of Bruton’s Tyrosine Kinase Inhibitor Specificity, Potency, and Biological Effects: Insights into Covalent and Noncovalent Mechanistic Signatures”
Antonia C. Darragh, Andrew M. Hanna, Justin Lipner, Alastair J. King, Nicole B. Servant, Mirza Jahic
Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Click any figure to enlarge with its caption.
Figure 1Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsChronic Lymphocytic Leukemia Research · HER2/EGFR in Cancer Research · Phagocytosis and Immune Regulation
Description of correction being made to the manuscript file: We would like to correct Figure 3. There should only be a blue bar in the graph for remibrutinib (there should not be an additional gray bar with a black outline for remibrutinib). The corrected figure is below.